Top-News

uniQure Aktie News

Aktie
WKN:  A1XDTV ISIN:  NL0010696654 US-Symbol:  QURE Branche:  Biotechnologie Land:  Niederlande
21,80 $
-0,94 $
-4,13%
18,711 € 16:32:29 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,41 Mrd. €
Streubesitz
5,07%
KGV
-3,60
Index-Zuordnung
-

uniQure News

24.09.25 - GlobeNewswire
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~
24.09.25 - GlobeNewswire
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a ...
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
05.09.25 - GlobeNewswire
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme ...
29.07.25 - GlobeNewswire
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
22.07.25 - GlobeNewswire
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
11.06.25 - GlobeNewswire
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure ...
02.06.25 - GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~
29.05.25 - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
~ No serious adverse events and 92% reduction in seizure frequency observed in the  first trial participant through first five months of follow up ~ ~ Data to be presented today at ...
09.05.25 - GlobeNewswire
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~
05.05.25 - GlobeNewswire
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
17.04.25 - GlobeNewswire
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
27.02.25 - GlobeNewswire
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease; Initiated ...
07.02.25 - PR Newswire
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-​drlb) Four Years Post-​Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with ...
03.02.25 - GlobeNewswire
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of ...
30.01.25 - GlobeNewswire
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate ...
08.01.25 - GlobeNewswire
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies ...
07.01.25 - GlobeNewswire
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies ...
10.12.24 - GlobeNewswire
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »